Clindamycin

CHEMBL1753 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
2-3 hours
Bioavailability
Protein Binding
Molecular Weight
425.0 g/mol
LogP
2.2
Phase
4

By binding the 50S ribosomal subunit and blocking protein synthesis, clindamycin arrests bacterial growth, and it is especially valued against anaerobic bacteria and certain drug-resistant organisms. It treats skin, respiratory, and soft-tissue infections. Marketed as Cleocin and in topical acne products, the compound has the formula C18H33ClN2O5S. Disruption of gut flora can predispose to Clostridioides difficile colitis, a recognized risk of its use.

An antibiotic that stops bacterial growth by blocking protein synthesis, effective against a wide range of skin, respiratory, and soft tissue infections. It is particularly valued for treating infections caused by anaerobic bacteria and certain drug-resistant organisms.

น้ำหนักโมเลกุล

424.9830 g/mol

LogP

2.20

TPSA

128.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

หมวดหมู่ยา

กลไกการออกฤทธิ์

Binds 50S ribosomal subunit inhibiting protein synthesis.

Pharmacokinetics (PK)

Half-Life 2-3 hours

Pharmacodynamics (PD)

กลไก

Binds 50S ribosomal subunit inhibiting protein synthesis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1

InChI

InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1

Molecular Formula

C18H33ClN2O5S

HBD / HBA

4 / 7

พันธะที่หมุนได้

7

อะตอมหนัก

27

No targets recorded

Target interaction data is not yet available for this drug.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An antibiotic that stops bacterial growth by blocking protein synthesis, effective against a wide range of skin, respiratory, and soft tissue infections. It is particularly valued for treating infections caused by anaerobic bacteria and certain drug-resistant organisms.

Binds 50S ribosomal subunit inhibiting protein synthesis.

Key pharmacokinetic parameters for Clindamycin: Half-life: 2-3 hours.

Yes, Clindamycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1753. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 446598. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.